Stryker Corp Q1 2023 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Great. I'll also add my congratulations on a really impressive quarter here. Maybe to focus in ortho, I was kind of blown away by how good the growth rates were in hip, knee and extremity. Would love to get a little more color on exactly what you're seeing there, how much the anterior hip stem is helping you in hip. What's going on in knee? And any color you could give on the trauma and extremities business, and what's driving the trends there?

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Maybe as a follow-up, your medical came in another really good quarter there. ProCuity launch continued strong. We heard one of your competitors, specifically in the bed market, talk about a weaker capital environment. So is that something you're seeing in some of the less revenue-generating capital equipment items? And any color you could give specifically in medical and how the beds are going?

Question: Danielle Joy Antalffy - UBS Investment Bank, Research Division - Analyst : Congrats on a really strong start to the year. Just one quick question for me, and sorry to harp on this, it has come up a few times on the call. But just as we look at the margins, not a lot of margin upside in the quarter. I appreciate you still have inflationary pressures and inventory rolling off the balance sheet that's impacting that. But wondering if you could talk a little bit more about anything specific that happened in the quarter given such a strong sales beat and you're talking positive pricing commentary. So just sort of reconciling in-line margins given the extent of the sales beat.